Intelligent Bio Solutions INC 10-Q quarterly reports

Intelligent Bio Solutions Inc. announced its third-quarter fiscal year 2026 results, showcasing a 46% year-over-year revenue increase driven by new customer acquisition and strong re-order rates for consumables.

Intelligent Bio Solutions Inc. reported a significant 47% revenue increase in Q2 2026, driven by new customers and re-orders, alongside a $10 million private placement, despite continued net losses and identified material weaknesses in internal controls.

Intelligent Bio Solutions Inc. reported record quarterly revenue and improved gross profit, but faces substantial doubt about its ability to continue as a going concern and delays in FDA clearance.

Intelligent Bio Solutions reports a decrease in revenue for Q3 2025 but highlights an improved gross profit margin driven by strategic sales mix and operational streamlining.

Intelligent Bio Solutions Inc. announces its financial results for the quarter ended December 31, 2024, alongside key operational achievements including the FDA 510(k) submission and new strategic partnerships.

Intelligent Bio Solutions Inc. saw a revenue increase in the first quarter of 2025, but ongoing research and development costs contributed to a net loss.

Intelligent Bio Solutions Inc. reports increased revenue for Q3 2024, driven by its Intelligent Fingerprinting Products, but continues to experience operating losses and identifies material weaknesses in internal controls.

Intelligent Bio Solutions Inc. saw a significant increase in revenue but also experienced a larger net loss in the second quarter of fiscal year 2024 compared to the same period last year.